AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...

AstraZeneca said on Friday it has agreed to a research deal with Chinese drugmaker CSPC Pharmaceuticals worth up to $5.22 ...

AstraZeneca has returned to recent licensing partner CSPC Pharmaceuticals with $110 million in upfront cash to start work on ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Drugmaker AstraZeneca revealed on Friday that it has entered a strategic research collaboration with Chinese firm CSPC Pharmaceuticals Group.

For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting ...

Sanjeev Kumar Panchal has stepped down as Managing Director of AstraZeneca Group. The company has appointed Praveen Rao ...

MSFT, AZN, and BLK earn praise in fresh Zacks reports, with AI, pharma pipelines, and AUM growth fueling long-term outlooks.

The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting -- loss of relevancy" says Susan Galbraith, EVP of Oncology R&D at AstraZeneca.

Understand every aspect of the global economy – and know how to make your next move.

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.